Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Stati Uniti - inglese - NLM (National Library of Medicine)

watson laboratories, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - tablet - 10 mg - therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. in hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: in patients with clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated total-c, ldl-c, apob, and tg levels and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).8 pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (fredrickson type iv). pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii)

Stati Uniti - inglese - NLM (National Library of Medicine)

rebel distributors corp - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin 10 mg - therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. in hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction - reduce the risk of undergoing myocardial revascularization procedures - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated total-c, ldl-c, apob, and tg levels and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).8 pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (fredrickson type iv). pravastatin sodi

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablet, usp is indicated to: -   reduce the risk of myocardial infarction (mi). -   reduce the risk of undergoing myocardial revascularization procedures. -   reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablet is indicated to: -   reduce the risk of total mortality by reducing coronary death. -   reduce the risk of mi. -   reduce the risk of undergoing myocardial revascularization procedures. -  

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).